Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease

Area of Science:

• Cardiology
• Biochemistry
• Public Health

Background:

• Cardiovascular disease (CVD) risk assessment relies heavily on total cholesterol and high-density lipoprotein cholesterol (HDL-C).
• The added value of other lipid measurements beyond HDL-C for CVD risk prediction remains debated.

Purpose of the Study:

• To evaluate the incremental predictive utility of non-HDL-C, LDL-C, and apolipoproteins (ApoA1, ApoB) in addition to standard lipids for CVD risk.
• To compare the predictive performance of different lipid markers in both non-statin and statin users.

Main Methods:

• Analysis of lipid profiles and CVD events in a large UK Biobank cohort (n=346,686) without baseline CVD or statin use.
• Cox proportional hazards models were used to assess associations of lipids with CVD, adjusting for classical risk factors.
• Predictive utility was quantified using C-index and net reclassification index, with validation in statin users.

Main Results:

• Apolipoprotein B (ApoB), LDL-C, and non-HDL-C showed strong correlations with CVD risk, similar to each other.
• Adding ApoB or LDL-C to a model with total cholesterol and HDL-C did not significantly improve CVD risk prediction.
• In statin users, non-HDL-C and ApoB improved risk prediction over classical factors, but adding ApoB to non-HDL-C provided no further benefit.

Conclusions:

• Nonfasting measurements of total cholesterol and HDL-C are adequate for capturing lipid-associated CVD risk.
• No significant improvement in CVD risk prediction is gained by incorporating apolipoproteins or LDL-C beyond standard lipid measures.